Event Details
Recurring/Ongoing
Description
Major investor, medical and scientific meetings
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| Scientific Community | person | 0 | View Entity |
| Fund Managers | person | 49 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024054.jpg
This document is page 43 of a confidential investment memorandum describing the 'Deal Sourcing & Investment Process' for a fund referred to as 'NLV'. It details the Fund Managers' strategy of tracking biopharma companies (specifically in Oncology, Infectious Disease, and CNS) and leveraging a high-level network of industry executives and scientists to identify investment opportunities. The page bears a House Oversight Bates stamp, indicating it was part of a congressional investigation.
Related Events
Events with shared participants
NLV-I Fund Managers began investing
2005-06-01 • N/A
NLV-I completed its new investment period
2008-01-01 • N/A
NLV-II Fund Managers began investing
2008-01-01 • N/A
Victim had interview with Epstein Victims Compensation Fund managers.
2021-04-06 • Unknown
Client interview with Epstein Victims Compensation Fund managers.
2021-04-06 • Unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event